Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06335927 | HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC | unknown | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05048524 | Peri-operative SLOG for Localized Pancreatic Cancer | unknown | Phase 2 | 64 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| Pancreatic Cancer & Surgical Resection |
| unknown |
| — |
| 30 |
| Methodist Health SystemOTHER |
| 1 |
| Mar 27, 2024 |
| clinicaltrials |
| NCT06323265 | A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer | unknown | — | 50 | Hebei Medical University Fourth HospitalOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06325267 | Clinical Characteristics of Primary Liver Cancer | unknown | — | 1,000 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06332287 | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis | unknown | Phase 2 | 25 | Jiangsu Province Nanjing Brain HospitalOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06331650 | A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer | unknown | Phase 2 | 30 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT02619448 | Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC | unknown | Early Phase 1 | 12 | State University of New York - Upstate Medical UniversityOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06328049 | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC | unknown | Phase 2 | 30 | Taixing People's HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06328283 | The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of Hepatocellular Carcinoma in Cirrhotic Patients | unknown | — | 90 | Sohag UniversityOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT05305820 | Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy(PANO) | unknown | N/A | 36 | Dublin City UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT05400239 | SOTO: Treatment Sensitivity of Organoids to Predict Treatment Outcome | unknown | — | 60 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06322745 | Thulium Beam Coagulation Versus Suture Renorrhaphy for Hemostasis of Tumor Bed in Laparoscopic Partial Nephrectomy | unknown | N/A | 30 | Al-Azhar UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06008522 | Safety and Feasibility of Immuno-OCT(DETOUR) | unknown | N/A | 15 | University Medical Center GroningenOTHER | 0 | Mar 20, 2024 | clinicaltrials |
| NCT06321627 | Radiosensitivity of HPV-related Tumors: Towards a Genomic Approach(ICARUS) | unknown | — | 100 | European Institute of OncologyOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06321640 | Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.(POSITive) | unknown | — | 265 | European Institute of OncologyOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06317298 | Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy | unknown | N/A | 36 | Peking University First HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT04354324 | Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma | unknown | N/A | 254 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT05783570 | To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307 | unknown | Phase 1 | 12 | EutilexINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06311279 | End to End Versus Side to End Anastomosis After Anterior Resection of Cancer Rectum | unknown | N/A | 20 | Sohag UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06285058 | Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy | unknown | — | 1,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Mar 13, 2024 | clinicaltrials |
| NCT06304766 | Open Versus Laparoscopic Ablation of Liver Malignancies(OPTIMAL) | unknown | N/A | 80 | Rigshospitalet, DenmarkOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT04024358 | A New Scoring System for Perineural and Vascular Invasion in Pancreatic Cancer(VANISSh) | unknown | — | 500 | Massimo FalconiOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04062656 | Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG(IMAGINE) | unknown | Phase 2 | 21 | University Hospital, EssenOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05004974 | Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 20 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05872867 | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | unknown | Phase 1 | 54 | Wellmarker BioINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06097793 | KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial | unknown | Early Phase 1 | 12 | Kousai Bio Co., Ltd.OTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06302881 | Differentiating Tumor-stroma Ratio in Pancreatic Ductal Adenocarcinoma | unknown | — | 207 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT06304597 | Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy(PREDICT) | unknown | Phase 1 | 18 | University Medical Center GroningenOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06277674 | Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI | unknown | Phase 2 | 20 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06259721 | Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 22 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03549715 | NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma(NEMIO) | unknown | Phase 1 / Phase 2 | 121 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04605185 | Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 18 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05011227 | Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 100 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05472857 | Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression | unknown | Phase 1 | 30 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05910177 | Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin | unknown | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06225921 | Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas | unknown | Phase 1 | 6 | West China HospitalOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04597476 | A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and Neck | unknown | Phase 2 | 119 | Hi-Q Marine Biotech International, Ltd.INDUSTRY | 1 | Mar 5, 2024 | clinicaltrials |
| NCT05156177 | Correlation of Fecal Microbiome and Its Metabolites With Outcome of Radiotherapy in Head and Neck Carcinoma(COMRAD-HNSCC) | unknown | — | 40 | Institute of Oncology LjubljanaOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06293833 | Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan(ZORALCS) | unknown | N/A | 700 | University Hospital, AntwerpOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05124002 | Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 66 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05637788 | Artificial Intelligence and Hepatocellular Carcinoma(ARTIHCC) | unknown | — | 535 | Humanitas Clinical and Research CenterOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06229405 | Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data | unknown | — | 8,200 | Seoul National University HospitalOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06291779 | Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in Urine | unknown | — | 120 | Ho-Seong HanOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04739670 | Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer(BELLA) | unknown | Phase 2 | 31 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT06287320 | The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer | unknown | — | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT06284746 | Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer | unknown | Phase 2 | 80 | Lin ChenOTHER | 1 | Feb 29, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Mar 28, 2024source: clinicaltrials